MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation

Published:2015-05 Issue:5 Volume:2 Page:406-420
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Chen Tom T.,Filvaroff Ellen,Peng Jing,Marsters Scot,Jubb Adrian,Koeppen Hartmut,Merchant Mark,Ashkenazi Avi

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference59 articles.

1. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK);Axten;J. Med. Chem.,2012

2. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells;Bauer;Mol. Cancer Ther.,2006

3. Stringent requirement for HRD1, SEL1L, and OS-9/XTP3-B for disposal of ERAD-LS substrates;Bernasconi;J. Cell Biol.,2010

4. Ubiquitin and the control of protein fate in the secretory and endocytic pathways;Bonifacino;Annu. Rev. Cell Dev. Biol.,1998

5. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis;Bonnesen;Lung Cancer,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of an enzyme-linked immunosorbent assay test-system for bevacizumab concentration determing in biological fluids;Drug development & registration;2024-04-26

2. Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer;Cancers;2023-04-28

3. Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer;2023-03-31

4. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management;Clinical Lung Cancer;2022-06

5. Phase II Study of Cabozantinib in Patients With Bone Metastasis;The Oncologist;2022-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3